Gemtuzumab ozogamicin - Wikipedia
Gemtuzumab ozogamicin is a recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ antibody hP67.6) covalently attached to the cytotoxic antitumor antibiotic calicheamicin (N-acetyl-γ-calicheamicin) payload via a bifunctional linker (4-(4-acetylphenoxy)butanoic acid).
Ozogamicin - Wikipedia
The term ozogamicin in the names of monoclonal antibodies or antibody-drug conjugates indicates that they are linked to a cytotoxic agent from the class of calicheamicins. [2]
Inotuzumab ozogamicin - Wikipedia
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [4][5] It is administered by intravenous infusion. [4][5]
Inotuzumab ozogamicin (intravenous route) - Mayo Clinic
Inotuzumab ozogamicin injection is used to treat acute lymphoblastic leukemia (ALL) that has come back or after other medicines did not work well. Leukemia is a type of cancer where the body makes abnormal white blood cells. Inotuzumab ozogamicin is an …
MYLOTARG™ (gemtuzumab ozogamicin) | Pfizer Medical …
MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.
Gemtuzumab Ozogamicin - NCI - National Cancer Institute
Gemtuzumab ozogamicin is approved to treat: Acute myeloid leukemia that is CD33 positive. It is used in adults and children aged 1 month and older with newly-diagnosed disease. It is used in adults and children aged 2 years and older whose disease has relapsed or is refractory (does not respond to treatment).
Gemtuzumab ozogamicin Uses, Side Effects & Warnings - Drugs.com
2024年9月13日 · Gemtuzumab ozogamicin is a monoclonal antibody linked to a chemotherapy drug. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.
FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML
On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML)...
MYLOTARG™ (gemtuzumab ozogamicin) Clinical Pharmacology
Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 antigen. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker.
Gemtuzumab ozogamicin: Uses, Interactions, Mechanism of …
2005年6月13日 · Gemtuzumab ozogamicin is a monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis.